مقاله‌های دارای تعهدات انتشار عمومی - Jesper B Andersenبیشتر بدانید
جای دیگری دردسترس نیست: ۱۳
مرور
Functional and genetic deconstruction of the cellular origin in liver cancer‏
JU Marquardt, JB Andersen, SS Thorgeirsson‏
Nature Reviews Cancer 15 (11), 653-667, 2015‏
تعهدات: US National Institutes of Health, German Research Foundation, Volkswagen …‏
مرور
Metabolic rearrangements in primary liver cancers: cause and consequences‏
L Satriano, M Lewinska, PM Rodrigues, JM Banales, JB Andersen‏
Nature reviews Gastroenterology & hepatology 16 (12), 748-766, 2019‏
تعهدات: Danish Council for Independent Research, Banking Foundation "la Caixa …‏
مرور
Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma‏
D Høgdall, M Lewinska, JB Andersen‏
Trends in cancer 4 (3), 239-255, 2018‏
تعهدات: Danish Council for Independent Research‏
مرور
Epigenome remodeling in cholangiocarcinoma‏
CJ O’Rourke, J Lafuente-Barquero, JB Andersen‏
Trends in cancer 5 (6), 335-350, 2019‏
تعهدات: Danish Council for Independent Research, European Commission‏
مرور
E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment‏
F González-Romero, D Mestre, I Aurrekoetxea, CJ O'Rourke, ...‏
Cancer research 81 (11), 2874-2887, 2021‏
تعهدات: Banking Foundation "la Caixa", European Commission, Government of Spain‏
مرور
Application of patient‐derived liver cancer cells for phenotypic characterization and therapeutic target identification‏
D Castven, D Becker, C Czauderna, D Wilhelm, JB Andersen, S Strand, ...‏
International journal of cancer 144 (11), 2782-2794, 2019‏
تعهدات: German Research Foundation, Volkswagen Foundation‏
مرور
Molecular profiling of intrahepatic cholangiocarcinoma: The search for new therapeutic targets‏
DVNP Oliveira, S Zhang, X Chen, DF Calvisi, JB Andersen‏
Expert Review of Gastroenterology & Hepatology 11 (4), 349-356, 2017‏
تعهدات: Danish Council for Independent Research, European Commission‏
مرور
High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy‏
C Quintavalle, K Burmeister, S Piscuoglio, L Quagliata, E Karamitopoulou, ...‏
Molecular carcinogenesis 56 (9), 2146-2157, 2017‏
تعهدات: Swiss National Science Foundation, Swiss Cancer League‏
مرور
Mutational signatures and processes in hepatobiliary cancers‏
E Zhuravleva, CJ O’Rourke, JB Andersen‏
Nature Reviews Gastroenterology & Hepatology 19 (6), 367-382, 2022‏
تعهدات: Danish Council for Independent Research, European Commission‏
مرور
Immunogenomics of cholangiocarcinoma‏
V Gehl, CJ O’Rourke, JB Andersen‏
Hepatology, 10.1097, 2023‏
تعهدات: Danish Council for Independent Research, European Commission‏
مرور
Involvement of Epigenomic Factors in Bile Duct Cancer‏
M Rogalska-Taranta, JB Andersen‏
Seminars in Liver Disease 42 (02), 202-211, 2022‏
تعهدات: Danish Council for Independent Research‏
مرور
Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities‏
D Høgdall, CJ O'Rourke, JB Andersen‏
Advances in cancer research 156, 343-366, 2022‏
تعهدات: Danish Council for Independent Research‏
مرور
Stromal yin‐yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma‏
JB Andersen‏
Hepatology 76 (5), 1233-1236, 2022‏
تعهدات: Danish Council for Independent Research‏
جای دیگری دردسترس است: ۱۱۴
مرور
Cholangiocarcinoma 2020: the next horizon in mechanisms and management‏
JM Banales, JJG Marin, A Lamarca, PM Rodrigues, SA Khan, LR Roberts, ...‏
Nature reviews Gastroenterology & hepatology 17 (9), 557-588, 2020‏
تعهدات: US National Institutes of Health, Danish Council for Independent Research …‏
مرور
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)‏
JM Banales, V Cardinale, G Carpino, M Marzioni, JB Andersen, ...‏
Nature reviews Gastroenterology & hepatology 13 (5), 261-80, 2016‏
تعهدات: UK Medical Research Council‏
مرور
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties‏
C Coulouarn, VM Factor, JB Andersen, ME Durkin, SS Thorgeirsson‏
Oncogene 28 (40), 3526-3536, 2009‏
تعهدات: US National Institutes of Health‏
مرور
Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles‏
F Farshidfar, S Zheng, MC Gingras, Y Newton, J Shih, AG Robertson, ...‏
Cell reports 18 (11), 2780-2794, 2017‏
تعهدات: US National Institutes of Health‏
مرور
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors‏
JB Andersen, B Spee, BR Blechacz, I Avital, M Komuta, A Barbour, ...‏
Gastroenterology 142 (4), 1021-1031. e15, 2012‏
تعهدات: US National Institutes of Health‏
مرور
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas‏
P Wang, Q Dong, C Zhang, PF Kuan, Y Liu, WR Jeck, JB Andersen, ...‏
Oncogene 32 (25), 3091-3100, 2013‏
تعهدات: US National Institutes of Health‏
مرور
Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients‏
L Quagliata, MS Matter, S Piscuoglio, L Arabi, C Ruiz, A Procino, M Kovac, ...‏
Hepatology 59 (3), 911-923, 2014‏
تعهدات: US National Institutes of Health, German Research Foundation, Swiss Cancer …‏
اطلاعات انتشارات و تأمین بودجه به‌طورخودکار توسط برنامه رایانه‌ای تعیین می‌شود.